Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

ConclusionConcomitant administration of selexipag and strong inhibitors of CYP2C8 must be avoided, whereas when coadministered with inducers of CYP2C8, dose adjustments of selexipag should be envisaged.

Source: British Journal of Clinical Pharmacology - August 16, 2017 Category: Drugs & Pharmacology Authors: Shirin Bruderer, Marc Petersen ‐Sylla, Margaux Boehler, Tatiana Remeňová, Atef Halabi, Jasper Dingemanse Tags: DRUG INTERACTIONS Source Type: research